MedTrace Logo

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

NCT03167411 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-05-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with one of the most commonly prescribed glucagon-like peptide 1 receptor agonist (GLP-1 RA) exenatide. The study will also evaluate how safe the study drug is and how well the study drug is tolerated when administered with exenatide injection.

Conditions

  • Type2 Diabetes Mellitus

Interventions

DRUG

Bexagliflozin

Bexagliflozin tablets, 20 mg

DRUG

Exenatide Injection

Byetta® (Exenatide), 10 ug, bid, subcutaneous injection

Sponsors & Collaborators

  • Theracos

    lead INDUSTRY

Principal Investigators

  • Mason Freeman, M.D. · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-24
Primary Completion
2017-06-29
Completion
2017-06-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03167411 on ClinicalTrials.gov